XpertPatient Launches Survivor-Led Education Platform for Newly Diagnosed Cancer Patients
Nyenta.com/10342974

NEW YORK - Nyenta -- XpertPatient.com today announced the launch of XpertGuided™, a survivor-led oncology education platform designed to support newly diagnosed and progressed cancer patients and caregivers during the most critical phases of their journey: the pre-treatment decision window (Day 1 through Week 5).

When a cancer diagnosis turns your world upside down, who do you turn to?  The moment is unlike any other. Patients and their families are suddenly flooded with information they don't yet have the language to process — and forced to make life-altering decisions they never expected to face. Most turn to the internet. What they find rarely reflects what they need.

XpertPatient.com is changing that.

More on Nyenta.com

• Kingston Rotary's Mutt Strutt Returns Sunday, June 7, this year at Gallo Park
• Robert J. Bradshaw's AYE is a Gripping Dual Reality Thriller Exploring the Increasingly Blurred Line Between Humanity and Technology
• Bangxing Silicone Revolutionizes Silicone Baby Product Partnerships: Low MOQ Support + VIP Long-Term Win-Win Programs
• Wnode - The First Granny‑Proof DePIN Compute Mesh, Turns Idle Hardware Into a People‑Owned
• SteelTree Announces Launch of Its Operational Decision Intelligence Service

XpertGuided™ addresses this gap by connecting patients with survivors who have experienced similar diagnoses and treatment decisions, providing real-world guidance, emotional support, and practical insight when it matters most.

The platform delivers stage-specific, easy-to-understand education shaped by lived experience and enhanced by AI to simplify complex clinical information and personalize the experience based on patient needs.

"XpertGuided is redefining how patients experience cancer education at the moment they need it most," said Risa L. Arin, Founder and CEO of XpertPatient. "By combining survivor insights and our award-winning design, we are helping patients & caregivers better understand their options—while enabling brand engagement during critical decision-making moments."

For pharmaceutical companies, XpertPatient provides a new model for oncology engagement—enabling brands to reach high-intent audiences at diagnosis and progression, when treatment decisions are actively being evaluated.

More on Nyenta.com

• Advanced AI Capabilities Reflected by Upcoming Company Name and Stock Symbol Change for Evolving Pre-Owned Boat Dealer: Off The Hook YS: N Y S E: OTH
• AI-Driven Defense Expansion, Autonomous Systems and Israeli Aerospace Manufacturing Platform: VisionWave Holdings (N A S D A Q: VWAV)
• AI Predicts the Most Likely 2026 FIFA World Cup Winner
• "Jim Peters At Night" Cracks Top One Percent of TikTok Views
• The AI Production Shift: Why Game Development Is Entering Its Most Accelerated Phase

Key capabilities include:

• Precision reach at diagnosis and disease progression
• Survivor-led, stage-specific education experiences
• Long-duration engagement in a premium, brand-safe environment
• 100% share of voice sponsorships aligned to cancer type and treatment stage

This approach enables engagement during the highest-value pre-treatment decision window, when patients are most receptive to education and guidance.

The XpertGuided experience is currently live within the XpertPatient Breast Cancer Center with additional Cancer Centers launching later in 2026.

Reach out today to learn about available Flagship Sponsorship opportunities.

About XpertPatient
XpertPatient.com is a premium oncology platform connecting newly diagnosed patients and caregivers with survivor-led guidance—enabling pharmaceutical brands to engage high-intent audiences during the highest-value pre-treatment decision window.